What Is a Normal Supply Cost as a Percentage of Revenue for a Cardiovascular OBL?
Supply cost as a percentage of revenue for a cardiovascular OBL does not have a single normal figure. It has a range determined by procedure mix, device and implant intensity, case volume, and commodity supply cost position relative to peer independent facilities. Published ASC benchmarks provide a starting orientation. However, the cardiovascular OBL operates under a cost structure distinct enough from multi-specialty ASCs that aggregate figures obscure more than they reveal. The number that matters is not the category average. It is where your facility sits within the range, and why.
What Published Benchmarks Show and Where They Stop
Published supply cost benchmarks for independent ASCs typically place total supply and drug costs between 18 and 28 percent of net revenue. According to VMG Health’s multi-specialty ASC benchmarking data, the average facility allocates 26.3 percent of its operating budget to drugs and medical supplies. However, multi-specialty ASC averages aggregate across facility types with materially different cost structures. A cardiovascular OBL running complex interventional procedures carries a fundamentally different supply cost composition than a general surgery ASC, an orthopedic facility, or a GI center.
For a cardiovascular OBL, two distinct cost layers drive the supply cost percentage. The first is device and implant costs. Stents, catheters, guidewires, and other procedure-specific inputs carry per-case costs that vary by procedure complexity and manufacturer contract. Negotiated at the case level, these costs are largely non-recoverable through operational changes. They establish a cost floor unique to cardiovascular and vascular interventional work that is not reflected in multi-specialty averages.
The second layer is commodity supply costs. Drugs, contrast agents, saline, procedure packs, vascular access supplies, and general consumables run through every case regardless of complexity. This layer reprices on distributor contract cycles the facility does not control, in increments that individually appear immaterial, and it constitutes the portion of the supply cost percentage with the most recoverable variance between facilities at similar volume and procedure mix. It is also the portion that published benchmarks are least equipped to isolate, because it requires SKU-level comparison against peer independent facilities rather than aggregate figures drawn across dissimilar facility types.
Why the Cardiovascular OBL Benchmark Is a Narrower Question Than It Appears
The meaningful benchmark for a cardiovascular OBL’s supply cost as a percentage of revenue is not what the average ASC spends. It is what comparable independent cardiovascular and vascular procedural facilities at similar case volume and procedure mix actually spend on the same inputs. That is a materially narrower comparison, and it is one that most published benchmarks do not attempt to make.
Furthermore, within that narrower comparison, the variance between facilities is driven by two distinct forces that require different responses. Device and implant cost variance reflects procedure volume, manufacturer relationships, and contract negotiation outcomes. Commodity supply cost variance reflects the purchasing position the facility holds relative to the market for independent operators at its volume. As examined in prior work on what remains after supply and drug costs, this second category of variance does not surface in standard financial reporting, and it is not corrected by volume growth or procedure mix changes. It requires a direct comparison against what peer independent cardiovascular OBLs pay for the same commodity inputs.
Most independent cardiovascular OBLs have never seen that comparison. Not because it is unavailable in principle, but because the data required to construct it has not historically been accessible to independent operators as a matter of course. That data is invoice-level commodity pricing from peer independent facilities at comparable volume and procedure mix. That benchmark exists. Whether it has ever been put in front of the right facility is a different matter.
Reading Your Supply Cost Percentage Against a Relevant Standard
A cardiovascular OBL whose supply costs represent 32 percent of net revenue may be running a clinically appropriate cost structure for its procedure mix, or it may be carrying commodity supply costs above what comparable independent facilities pay for the same inputs. Those are different conditions. Device intensity explains one. Purchasing position explains the other. Standard reporting cannot distinguish between them, because it measures what the facility spent, not whether that spending reflects market rates for the commodity layer underneath its clinical operation.
The supply cost percentage only tells a physician-owner something actionable when it is separated into its two components and each is evaluated against the right reference point. Device and implant costs belong against manufacturer contract benchmarks at the procedure level. Commodity supply costs belong against what peer independent cardiovascular OBLs at equivalent volume actually pay for the same SKUs. Without that separation, the aggregate percentage reflects the clinical operation and the purchasing position simultaneously, and the portion that is addressable remains invisible.
If you want to understand where your cardiovascular OBL’s commodity supply cost position sits relative to peer independent facilities at your volume and procedure mix, request your complimentary supply cost analysis at vantumpartners.com. You see your position against documented market rates. No obligation.
Frequently Asked Questions
What is a normal supply cost as a percentage of revenue for a cardiovascular OBL?
A normal supply cost as a percentage of revenue for a cardiovascular OBL is not a single published figure. It reflects procedure mix, device and implant intensity, case volume, and the commodity supply cost position the facility holds relative to comparable independent cardiovascular and vascular procedural facilities. Published ASC benchmarks place total supply and drug costs between 18 and 28 percent of net revenue for multi-specialty facilities, but cardiovascular OBLs carry higher per-case device costs that push this figure higher. The more meaningful comparison is against independent cardiovascular OBLs at similar volume, not against multi-specialty averages.
How do device and implant costs affect supply cost percentage in a cardiovascular OBL?
Device and implant costs represent the procedure-specific layer of supply cost in a cardiovascular OBL. Stents, catheters, guidewires, and other interventional inputs carry per-case costs that vary by procedure complexity and manufacturer contract. These costs establish a cost floor unique to cardiovascular and vascular procedural work that is not reflected in multi-specialty ASC benchmarks. They are largely determined by procedure volume and clinical negotiation at the case level, which makes them distinct from commodity supply costs and requires a different reference point to evaluate meaningfully.
Why does commodity supply cost percentage vary between cardiovascular OBLs at similar volume?
Commodity supply costs in a cardiovascular OBL vary between facilities at similar volume because they reprice inside distributor relationships on contract cycles the facility does not control. Drugs, contrast agents, saline, vascular access supplies, and procedure packs adjust in increments that appear individually immaterial but accumulate over time. Two cardiovascular OBLs running identical procedure mixes at identical case volumes can carry materially different commodity supply cost percentages based entirely on the purchasing position each facility holds relative to the market for independent operators at its volume. That variance does not appear in standard financial reporting.
How do I know if my cardiovascular OBL’s supply cost percentage reflects market rates?
Knowing whether your cardiovascular OBL’s supply cost percentage reflects market rates requires separating device and implant costs from commodity supply costs and evaluating each against the appropriate reference point. Device costs belong against manufacturer contract benchmarks at the procedure level. Commodity supply costs belong against what comparable independent cardiovascular OBLs at equivalent volume actually pay for the same inputs. Without that separation, the aggregate supply cost percentage reflects both components simultaneously, and the portion that is addressable through market comparison remains invisible inside standard reporting.
What is the difference between supply cost benchmarks for ASCs and cardiovascular OBLs?
Published supply cost benchmarks for ASCs aggregate across facility types with materially different cost structures. A cardiovascular OBL running complex interventional procedures carries a higher per-case device and implant cost than general surgery, orthopedic, or GI facilities. Applying a multi-specialty ASC average to a cardiovascular OBL produces an irrelevant reference point that obscures the actual cost composition of the facility. The relevant benchmark for a cardiovascular OBL is drawn from independent cardiovascular and vascular procedural facilities at comparable case volume and procedure mix, not from aggregate figures across dissimilar facility types.